Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours
originating in the digestive tract. They have a characteristic morphology, are generally …

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of
mesenchymal origin. GIST spans a wide clinical spectrum that ranges from tumors with …

Importance Adjuvant imatinib is associated with improved recurrence-free survival (RFS)
when administered after surgery to patients with operable gastrointestinal stromal tumor …

Importance Three years of adjuvant imatinib mesylate therapy is associated with reduced
recurrence rates and improved overall survival in patients with high-risk primary …

Importance Little is known about whether the duration of adjuvant imatinib influences the
prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet …

Gastrointestinal stromal tumors are rare malignancies involving the intestinal tract. They are
now easily recognized using standard immunohistochemistry. Management in the past was …

Gastrointestinal stromal tumors (GIST) are rare neoplasms arising from the interstitial cell of
Cajal in the gastrointestinal tract. Two thirds of GIST in adult patients have c-Kit mutation and …

Simple Summary Gastrointestinal stromal tumors (GIST) are potentially malignant tumors
and require evidence-based surgical and/or medical treatment. Laparoscopy has similar …

Objective: To characterize the results of surgery for gastrointestinal stromal tumor (GIST) in
the pre and post-imatinib eras at a single institution and to identify current prognostic …

Background This document is a summary of the French Intergroup guidelines regarding the
management of gastrointestinal stromal tumours (GISTs) updated in December 2018 …